Mobile

A study which compares Rigosertib with standard of care treatment in patients with ineffective production of blood cells (myelodysplastic syndrome) who have undergone treatment with azacitidine or dec...

Mise à jour : Il y a 4 ans
Référence : NCT02562442

A study which compares Rigosertib with standard of care treatment in patients with ineffective production of blood cells (myelodysplastic syndrome) who have undergone treatment with azacitidine or decitabine without success

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is: • to compare the overall survival (OS) of patients in the rigosertib group vs the Physician`s Choice group, in all patients and in a subgroup of patients with IPSS-R (Revised International Prognostic Scoring System) very high risk.

Critère d'inclusion

  • myelodysplastic syndrome

Liens